# US 2023/0067666 A1 · Method for preparing coumarin compounds substituted by amidoalkyl at 3-position, the products and related intermediates thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0067666 A1
- Document ID: US20230067666A1
- Status: Published application
- Kind: A1
- Application number: 17/758,267
- Filed: 2020-12-30
- Published: 2023-03-02
- Earliest claimed: 2019-12-31
- Assignees: Fosun Orinove Pharmatech, Inc.
- Applicants: Fosun Orinove PharmaTech, Inc.
- Inventors: Qingping ZENG; Ruiping WANG; Jie DUAN; Xudong WEI
- Web page: https://patentgrep.com/patent/US20230067666A1

## CPC

- C07D 311/16: substituted in position 7
- C07D 413/06: linked by a carbon chain containing only aliphatic carbon atoms
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/14: of the thyroid hormones, e.g. T3, T4
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 13/10: of the bladder
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 31/22: for herpes viruses
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07D 295/185: from aliphatic carboxylic acids
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates to a method for preparing coumarin compounds substituted by amidoalkyl at 3-position, and related intermediates thereof. The method includes: Step (A): reacting a compound of formula (VI) with a compound of formula (V) to give a compound of formula (VII) wherein R1 and R2 are each independently selected from hydrogen, halogen, and —O(C1-8 alkyl), wherein the alkyl is optionally substituted with 1 or 2 groups selected from the group consisting of halogen, C1-8 alkyl substituted with 1-2 hydroxyl groups, —O(C1-8 alkyl); R3 is -L-C(O)NR5R6, L is C1-3 alkylene.

## Claims

### Claim 1

A method for the preparation of a compound of formula (VII), comprising
Step (A): reacting a compound of formula (VI) with a compound of formula (V) to give a compound of formula (VII)
wherein R1 and R2 are each independently selected from the group consisting of hydrogen, halogen, and —O(C1-8 alkyl), wherein the alkyl is optionally substituted with 1-2 groups selected from the group consisting of halogen, C1-8 alkyl substituted with 1-2 hydroxyl groups, —O(C1-8 alkyl);
R3 is -L-C(O)NR5R6, L is C1-3 alkylene;
R4 is —O(C1-6 alkyl);
R5 and R6 are each independently selected from the group consisting of hydrogen, C1-8 alkyl, C3-10 cycloalkyl, wherein the alkyl, cycloalkyl are optionally substituted with 1-2 groups selected from the group consisting of halogen, —O(C1-8 alkyl), —NH2, —NH(C1-8 alkyl), —N(C1-8 alkyl)2, five-to seven-membered heterocyclyl, wherein the heterocyclyl contains 1-2 heteroatoms selected from the group consisting of N, O, S, and the heterocyclyl is optionally substituted with 1-2 groups selected from the group consisting of C1-8 alkyl; or
R5 and R6 together with the N atom to which they are attached form a five- to seven-membered heterocyclyl, and the heterocyclyl optionally contains 1 additional heteroatom selected from the group consisting of N, O, S, and is optionally substituted with 1-2 groups selected from the group consisting of halogen, C1-8 alkyl, —O(C1-8 alkyl), —NH2, —NH(C1-8 alkyl), —N(C1-8 alkyl)2.

### Claim 2 (depends on 1)

The method of claim 1, wherein R1 and R2 are each independently selected from the group consisting of hydrogen, halogen and —O(C1-4 alkyl), wherein the alkyl group is optionally substituted with 1-2 groups selected from the group consisting of halogen, —O(C1-4alkyl); preferably, R1 and R2 are each independently selected from the group consisting of hydrogen, halogen and —O(C1-2 alkyl), wherein the alkyl is optionally substituted with halogen or methoxy; more preferably, R1 and R2 are each independently hydrogen, methoxy or

### Claim 3 (depends on 1)

The method of claim 1, wherein R4 is —O(C1-4 alkyl); —O(C1-2 alkyl); more preferably ethoxy.

### Claim 4 (depends on 1)

The method of claim 1, wherein L is methylene or ethylene, preferably methylene.

### Claim 5 (depends on 1)

The method of claim 1, wherein R5 and R6 are each independently selected from the group consisting of hydrogen, C1-6 alkyl, wherein the alkyl is optionally substituted with 1-2 groups selected from the group consisting of halogen, —O(C1-6 alkyl), —NH2, —NH(C1-6 alkyl), —N(C1-6 alkyl)2, five- to seven-membered heterocyclyl, wherein the heterocyclyl contains 1-2 heteroatoms selected from N, O, S, and the heterocyclyl is optionally substituted with 1-2 groups selected from the group consisting of C1-6 alkyl; or
R5 and R6 together with the N atom to which they are attached form a five- to seven-membered heterocyclyl, and the heterocyclyl optionally contains 1 additional heteroatom selected from the group consisting of N, O, S, and is optionally substituted with 1-2 groups selected from the group consisting of halogen, C1-6 alkyl, —O(C1-6 alkyl), —NH2, —NH(C1-6 alkyl), —N(C1-6 alkyl)2;
preferably, R5 and R6 are each independently selected from the group consisting of hydrogen, C1-4 alkyl, wherein the alkyl is optionally substituted with 1-2 groups selected from the group consisting of halogen, —O(C1-2 alkyl), —NH(C1-2 alkyl), —N(C1-2 alkyl)2, five- to seven-membered heterocyclyl, wherein the heterocyclyl contains 1-2 heteroatoms selected from N, O, S, and at least one of the heteroatoms is N, and the heterocyclyl is optionally substituted with 1-2 groups selected from the group consisting of C1-4 alkyl; or
R5 and R6 together with the N atom to which they are attached form a five- to seven-membered heterocyclyl, and the heterocyclyl optionally contains 1 additional heteroatom selected from the group consisting of N, O, S, and is optionally substituted with 1-2 groups selected from the group consisting of halogen, C1-4 alkyl, —O(C1-2 alkyl), —NH(C1-2 alkyl), —N(C1-2 alkyl)2;
more preferably, R5 and R6 are each independently selected from the group consisting of hydrogen, C1-2 alkyl, wherein the alkyl is optionally substituted with 1-2 groups selected from the group consisting of methoxy, dimethylamino, morpholinyl, piperidinyl or piperazinyl, wherein the morpholinyl, piperidinyl or piperazinyl is optionally substituted with methyl; or
R5 and R6 together with the N atom to which they are attached form a morpholinyl, piperidinyl or piperazinyl, wherein the morpholinyl, piperidinyl or piperazinyl is optionally substituted with methyl;
more preferably, R5 and R6 are each independently selected from the group consisting of hydrogen, C1-2 alkyl, wherein the alkyl is substituted with morpholinyl; or
R5 and R6 together with the N atom to which they are attached form a morpholinyl group.

### Claim 6 (depends on 1)

The method of claim 1, wherein the compound of formula (VII) has the structure of the following compound 5A2, and the method for preparing the compound of formula (VII) comprises:
Step (A): reacting compound 1 with compound B1 to give compound 5A2

### Claim 7 (depends on 1)

The method of claim 1, wherein step (A) is carried out under an acidic condition, and/or the reaction temperature is −20° C. to 70° C., preferably −5° C. to 60° C., more preferably 20° C. to 50° C.

### Claim 8 (depends on 1)

A method for the preparation of a compound of formula (I), comprising the following step (A) and step (B)
Step (A): reacting a compound of formula (VI) with a compound of formula (V) to give a compound of formula (VII)
Step (B): preparing the compound of formula (I) from the compound of formula (VII)
wherein R1, R2, R3 and R4 are as defined in claim 1.

### Claim 9 (depends on 1)

An intermediate compound, wherein the structure is shown in the following formula (V):
wherein R3 and R4 are as defined in claim 1.

### Claim 10 (depends on 9)

The intermediate compound of claim 9, which is compound B1:

### Claim at position 11

11-12. (canceled)

### Claim 13

A crystal form I of the compound of the following formula, wherein the X-ray powder diffraction pattern of the crystal form I has characteristic peaks at diffraction angles (2θ) of about 8.44±0.2°, 13.11±0.2°, 15.70±0.2°, 19.73±0.2°, 21.00±0.2° and 22.91±0.2°,

### Claim 14 (depends on 13)

The crystal form I of claim 13, wherein the X-ray powder diffraction pattern of the crystal form I has characteristic peaks at diffraction angles (2θ) of about 8.44±0.2°, 10.91±0.2°, 10.68±0.2°, 13.11±0.2°, 15.70±0.2°, 17.54±0.2°, 19.73±0.2°, 21.00±0.2°, 22.91±0.2° and 26.27±0.2°,
preferably, the X-ray powder diffraction pattern of the crystal form I has characteristic peaks at diffraction angles (2θ) of about 8.44±0.2°, 10.91±0.2°, 10.68±0.2°, 13.11±0.2°, 15.70±0.2°, 16.90±0.2°, 17.54±0.2°, 19.73±0.2°, 21.00±0.2°, 22.91±0.2°, 26.27±0.2°, 28.64±0.2°.

### Claim 15 (depends on 13)

The crystal form I of claim 13, wherein the X-ray powder diffraction pattern of the crystal form I
has characteristic peaks at diffraction angles (2θ) as shown in Table 1; or
is substantially as shown in FIG. 1.

### Claim 16

(canceled)

### Claim 17 (depends on 13)

The crystal form I of claim 13, wherein the crystal form I satisfies at least one of the following (1) to (3):
(1) The thermogravimetric analysis pattern is substantially as shown in FIG. 2;
(2) The differential scanning calorimetry analysis pattern is substantially as shown in FIG. 3;
(3) The dynamic vapour sorption pattern is substantially as shown in FIG. 4.

### Claim 18 (depends on 13)

The crystalline form I of claim 13, wherein the crystal form I has an onset temperature of about 239° C.±5° C. and a peak temperature of about 242° C.±5° C. when characterized by DSC.

### Claim 19 (depends on 13)

The crystal form I of claim 13, which is an anhydrate crystal form.

### Claim 20 (depends on 13)

A method of preparing the crystal form I of claim 13, comprising:
Step i: after the reaction in step (B) is completed, concentrating the reaction solution and adding water and the compound seed crystal of formula (I) to induce crystallization;
Step ii: separating the crude product obtained in step i, stirring with a suitable solvent under a heating condition, then cooling, and isolating the compound of formula (I) in a crystalline state,
wherein
after separating the crude product and before stirring with a suitable solvent under a heating condition, step ii further comprises the step of rinsing the crude product with a suitable solvent; and/or
after isolating the compound of formula (I) in crystalline state, step ii further comprises the steps of rinsing with a suitable solvent and drying; and/or
the suitable solvent described in step ii is selected from the group consisting of a nitrile solvent or a mixed solvent of a nitrile solvent and water: preferably, the nitrile solvent is selected from the group consisting of acetonitrile, benzonitrile, phenylacetonitrile or a combination thereof, preferably acetonitrile; and/or
the heating temperature in step ii is preferably 40-80° C., more preferably 50-70° C.; and/or
the heating time of step ii is at least 2 h, preferably at least 4 h, more preferably at least 8 h.

### Claim 21

(canceled)

### Claim 22 (depends on 13)

A pharmaceutical composition comprising the crystal form I of claim 13 and one or more pharmaceutically acceptable carriers.

### Claim 23 (depends on 13)

A method for treating or preventing a disease, disorder or condition associated with the unfolded protein response or a disease, disorder or condition associated with a target of regulated IRE1-dependent decay, comprising administering to an individual in need thereof an effective amount of the crystal form I of claim 13;
wherein the disease, disorder or condition associated with an unfolded protein response is selected from the group consisting of B cell autoimmune disease, cancer and viral infection;
preferably,
the B cell autoimmune disease is selected from the group consisting of Addison's disease, antiphospholipid syndrome, aplastic anemia, autoimmune hemolytic anemias, autoimmune hepatitis, autoimmune hypophysitis, autoimmune lymphoproliferative disorders, autoimmune myocarditis, Churg-Strauss syndrome, epidermolysis bullosa acquisita, giant cell arteritis, Goodpasture's syndrome, Graves disease, Guillain-Barré syndrome, Hashimoto's thyroiditis, idiopathic thrombocytopenic purpura, IgA nephropathy, myasthenia gravis, pemphigus foliaceous, pemphigus vulgaris, polyarteritis nodosa, polymyositis/dermatomyositis, rheumatoid arthritis, scleroderma, Siögren's syndrome, systemic lupus erythematosus, Takayasu's arteritis and Wegener's granulomatosis; and/or
the cancer is a solid tumor selected from the group consisting of a breast tumor, a bone tumor, a prostate tumor, a lung tumor, an adrenal gland tumor, a bile duct tumor, a bladder tumor, a bronchial tumor, a nervous tissue tumor, a gallbladder tumor, a gastric tumor, a salivary gland tumor, a esophageal tumor, a small intestine tumor, a cervical tumor, a colon tumor, a rectal tumor, a liver tumor, an ovarian tumor, a pancreatic tumor, a pituitary adenoma and secretory adenoma; and/or
the cancer is a drug-resistant or radiation-resistant solid tumor; and/or
the cancer is a hematological tumor selected from the group consisting of a lymphoma, a leukemia and a monoclonal gammopathy of undetermined significance (MGUS); preferably, the lymphoma is selected from multiple myeloma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, and/or the leukemia is selected from acute and chronic types of lymphocytic leukemia and acute and chronic types of myeloid leukemias; and/or
the viral infection is an enveloped virus infection; preferably, the viral infection is an enveloped virus infection that utilizes an unfolded protein response pathway in replicating and forming infectious progeny: more preferably, the viral infection is selected from the group consisting of infections caused by measles virus, pox virus, Ebola virus (Ebola), Epstein Barr virus (EBV), cytomegalovirus (CMV), a virus of the genus Flavivirus, and hepatitis C virus (HCV); wherein the virus of the genus Flavivirus is preferably Japanese encephalitis virus or West Nile virus;
and
wherein the disease, disorder or condition associated with a target of regulated IRE1-dependent decay is selected from the group consisting of a neurological disorder, a disorder involving overproduction of insulin, and a disorder involving inflammation;
preferably, the neurological disorder is schizophrenia, the disorder involving overproduction of insulin is type II diabetes, the disorder involving inflammation is selected from the group consisting of glomerulonephritis, various forms of arthritis, multiple sclerosis and inflammatory bowel disease.

### Claim at position 23

24-25. (canceled)

### Claim 26 (depends on 22)

A method for treating or preventing a disease, disorder or condition associated with the unfolded protein response or a disease, disorder or condition associated with a target of regulated IRE1-dependent decay, comprising administering to an individual in need thereof an effective amount of the pharmaceutical composition of claim 22.
